Multimodality treatment of hepatocellular carcinoma : How field practice complies with international recommendations

Ten patients (24%) showed a partial resolution. Fourteen patients (33%) showed no response or a progression of thrombosis. One patient developed a non-lethal major bleeding event (haemoperitoneum three day after paracentesis) while 5 patients developed a non-major bleeding events during the study (14%). In all these patients but one FPX was discontinued. No significant change was observed in the platelet count before and during treatment (67×103/mm3 vs 68×103/mm3, p=N.S.). Conclusions: In patients with cirrhosis and marked thrombocytopenia, FPX seems to be effective and safe in the treatment of acute nonmalignant PVT.